NDAINTRAVENOUSSOLUTION
Approved
May 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BLOXIVERZ (neostigmine methylsulfate) by Sagent Pharmaceuticals is inhibitor. First approved in 2013.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BLOXIVERZ (neostigmine methylsulfate) is an acetylcholinesterase inhibitor administered intravenously that reverses neuromuscular blockade by increasing acetylcholine concentration in the synaptic cleft. It is used in perioperative settings to counteract the effects of nondepolarizing neuromuscular blocking agents used during anesthesia. The drug competes for the same receptor binding site as neuromuscular blockers, effectively restoring neuromuscular transmission.
Peak
Product is in peak commercial phase with moderate competitive pressure (30), suggesting stable team size and operational focus on market maintenance.
Mechanism of Action
inhibitor. By reducing the breakdown of acetylcholine, neostigmine methylsulfate induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents, and reverses the neuromuscular blockade.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Professionals joining the BLOXIVERZ team enter a mature, specialized perioperative product with zero currently linked job openings, suggesting selective hiring and a stable organizational footprint. Career advancement opportunities emphasize deep clinical expertise in neuromuscular physiology, perioperative medicine, and hospital formulary relationships rather than rapid expansion.
Medical Science Liaison
Worked on BLOXIVERZ at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.